Rhumbline Advisers lowered its position in Novartis AG (NYSE:NVS – Free Report) by 14.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 34,754 shares of the ...
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...
Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...
The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...
A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug ...
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...
Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.
Legal notices were served on January 8 to three officials concerned including the Governor of the Bangladesh Bank (BB) urging to stay hand over share of Taka 230 crore of Novartis Bangladesh to Radian ...
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...
Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...
Syngenta is continuing to grow its biologicals division with the recent acquisition of certain Novartis technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback